Consensus Celcuity Inc.

Stocks

CELC

US15102K1007

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 19/09/2026 +04			5-day change	1st Jan Change
80.61 ^USD	-5.06%		-3.40%	-19.18%

09-09	Celcuity Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM
08-26	Celcuity Inc Submits Supplemental New Drug Application to Fda for Revtorpyk (Gedatolisib) for Hr+/Her2-, Pik3ca Mutant Locally Advanced or Metastatic Breast Cancer	CI

Evolution of the Average Target: Celcuity Inc.

Evolution of the Target Price: Celcuity Inc.

Changes in Analyst Recommendations: Celcuity Inc.

98665dc6637e2c415d443a.VVxcizbHXIf8zqTdHJF2Iy9JV8ktbjSiokq49kAYA-k.JAgv2HiNA_Oji5Pvf8I6UVkMEJl_Vnvh7i32jCtZO6AKMCXFRrItxrOk5Q~6cce42dbb46251ce56c687e9b68dc44a

Analysts' recommendations: Celcuity Inc.

09-17	JPMorgan Initiates Celcuity With Overweight Rating, $157 Price Target	MT
05-04	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
05-04	HC Wainwright Upgrades Celcuity to Buy From Neutral, Adjusts Price Target to $165 From $94	MT
12-12	Wells Fargo Initiates Celcuity With Overweight Rating, $126 Price Target	MT
11-18	Celcuity Shares Fall After HC Wainwright Downgrade	MT
11-17	HC Wainwright Downgrades Celcuity to Neutral From Buy, Adjusts PT to $94 From $77	MT
11-17	HC Wainwright Downgrades Celcuity to Neutral From Buy, Price Target is $94	MT
11-13	Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share	RE
18/10/25	Celcuity Provides Update on Status of the Pik3ca Mutated Cohort of Phase 3 Viktoria-1 Trial and Releases Additional Data Analysis from Phase 1B Clinical Trial	CI
22/09/25	Guggenheim Initiates Celcuity at Buy With $110 Price Target	MT
26/08/24	LifeSci Capital Initiates Coverage on Celcuity With Outperform Rating, $27 Price Target	MT
22/07/24	Leerink Partners Starts Celcuity With Outperform Rating, $29 Price Target	MT
31/05/24	Needham Trims Price Target on Celcuity to $23 From $24, Maintains Buy Rating	MT
16/05/24	Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating	MT
28/03/24	Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating	MT
28/03/24	Needham Adjusts Price Target on Celcuity to $24 From $23, Keeps Buy Rating	MT
22/02/24	Stifel Initiates Celcuity With Buy Rating, Price Target is $40	MT
08/12/23	HC Wainwright Starts Coverage on Celcuity with Buy Rating, $27 Price Target	MT
17/05/22	Craig Hallum Adjusts Celcuity Price Target to $20 From $30, Maintains Buy Rating	MT
17/05/22	Needham Adjusts Celcuity's Price Target to $25 from $50, Keeps Buy Rating	MT
08/10/21	Celcuity : Canaccord Genuity Starts Celcuity at Buy With $50 Price Target	MT
07/09/21	Celcuity : Jefferies Starts Celcuity at Buy with $48 Price Target	MT
29/07/21	Celcuity : Cowen Initiates Coverage on Celcuity With Outperform Rating	MT
27/07/21	Celcuity : Needham Starts Celcuity at Buy With $50 Price Target	MT
12/04/21	Celcuity : HC Wainwright Adjusts Celcuity's Price Target to $30 From $19, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CELCUITY INC.					+99.42%
	WUXI APPTEC CO., LTD.					+16.92%
	ARGENX SE					+17.96%
	INSMED INCORPORATED					+66.29%
	WUXI BIOLOGICS (CAYMAN) INC.					+15.47%
	BIONTECH SE					+23.62%
	GENMAB A/S					+8.57%
	PHARMAESSENTIA CORPORATION					+18.41%
	EXELIXIS, INC.					-8.01%
	SUMMIT THERAPEUTICS INC.					+62.99%
	Average					+32.16%
	Weighted average by Cap.					+23.93%